Drugs.com - Clinical Trials

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

LEXINGTON, Mass.--(BUSINESS WIRE)--May 5, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today...

May 12, 2025 - 08:17
 0
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
LEXINGTON, Mass.--(BUSINESS WIRE)--May 5, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today...
Read More

Tags:

Previous Article

Why My Virgin Media Down (SOLUTIONS)

Next Article

Data Privacy Breaches: A Wake-Up Call for Hotel Operators

Related Posts

Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial

Orforglipron Demonstrated Statistically Significant Eff...

May 12, 2025  0

AI Screening for Opioid Use Disorder Associated with Fewer Hospital Readmissions

AI Screening for Opioid Use Disorder Associated with Fe...

May 12, 2025  0

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

FDA Announces Plan to Phase Out Animal Testing Requirem...

May 12, 2025  0